A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs TDENV LAV (Primary) ; TDENV PIV (Primary)
- Indications Dengue
- Focus Adverse reactions
- 02 May 2017 Status changed from recruiting to completed.
- 31 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
- 28 May 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2015, as reported by ClinicalTrials.gov record.